Neuromyelitis Optica Spectrum Disorder Market Demand Size, Share, Emerging Trends, Analysis and Forecasts to 2027

Neuromyelitis Optica Spectrum Disorder Market: Introduction

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory disorder of central nervous system which was previously known as Devic disease or neuromyelitis optica (NMO). It is a rare debilitating and lifelong disease characterized by inflammation in spinal cord and optic nerve.
People with neuromyelitis optica spectrum disorder experience symptoms such as paralysis, muscle weakness, and blindness. Neuromyelitis optica spectrum disorder is most common in non-Caucasian women

Key Drivers and Opportunities of Global Neuromyelitis Optica Spectrum Disorder Market

Rise in incidence of neuromyelitis optica spectrum disorder is likely propel the neuromyelitis optica spectrum disorder market. For instance, according to an article published in Neurology, in Denmark, the incidence of neuromyelitis optica spectrum disorder was 0.070 per 100,000 person-years and the prevalence was 1.09 per 100,000 in 2015.
Moreover, increase in research & development by key players is anticipated to drive the market. Several players are investing in development of products for the treatment of neuromyelitis optica spectrum disorder. Thus, key players have a strong pipeline.
In December 2019, F. Hoffmann-La Roche Ltd announced the pivotal phase III study of the investigational medicine satralizumab for the treatment of neuromyelitis optica spectrum disorder
In 2019, inebilizumab (Anti-CD19 mAb) completed phase III clinical trial for neuromyelitis optica spectrum disorder. It is offered by Viela Bio.
Satralizumab offered by Genentech is in phase III clinical trial. It is an investigational humanized monoclonal antibody that targets IL-6 receptor. It is being evaluated for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
Furthermore, introduction of new products by key players is anticipated to drive the neuromyelitis optica spectrum disorder market. For instance, in June 2019, Alexion Pharmaceuticals, Inc. received approval for Soliris injection for the treatment of neuromyelitis optica spectrum disorder in adult patients.
Emergence of new therapies for acute phase or prevention of neuromyelitis optica spectrum disorder creates lucrative opportunity for the market. Emerging therapies for acute phase and prevention are Bevacizumab (anti-VEGF mAb) and Alpha1-antitrypsin; and Eculizumab (anti-C5 mAb) and Rituximab (anti-CD20 mAb), respectively.

Are you a Start-up willing to make it Big in the Business? Grab an Exclusive PDF Brochure of Report

North America to Capture Major Share of Global Neuromyelitis Optica Spectrum Disorder Market

North America is expected to account for major share of the global neuromyelitis optica spectrum disorder market due to new product launch and approval. For instance, in October 2019, the U.S. Food and Drug Administration accepted Genentech’s Biologics License Application (BLA) for satralizumab for the treatment of neuromyelitis optica spectrum disorder in adults and adolescents. In December 2018, Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab granted the Breakthrough Therapy Designation from U.S. Food and Drug Administration. It is an investigational medicine for the treatment of neuromyelitis optica spectrum disorders and neuromyelitis optica.
The neuromyelitis optica spectrum disorder market in Asia Pacific is expected to grow at a rapid pace during the forecast period, owing to rise in prevalence of NMOSD. For instance, according to a study published in Neurology, in 2016, the prevalence of NMOSD was 4.1 per 100,000 in northern Japan and it was higher in females than males.